Immediate Impact

46 standout
Sub-graph 1 of 22

Citing Papers

AXL signaling in cancer: from molecular insights to targeted therapies
2025 Standout
Traditional Chinese medicine in lung cancer treatment
2025 Standout
2 intermediate papers

Works of Mingjun Li being referenced

Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.
2024
Silencing of Ribosomal Protein L34 (RPL34) Inhibits the Proliferation and Invasion of Esophageal Cancer Cells
2017

Author Peers

Author Last Decade Papers Cites
Mingjun Li 121 35 15 52 14 159
Minghe Li 112 16 28 53 14 198
Weijie Zhou 122 31 29 50 15 190
Yiming He 151 21 16 111 14 202
Prabhakar Pitta Venkata 125 33 20 46 15 225
Chengxuan Yu 120 16 17 59 22 203
Huazhen Liang 73 48 30 51 10 144
Fatemeh Alikarami‬ 103 32 12 23 14 173
Shibo Liu 122 32 14 49 21 207
Haijuan Xiao 134 50 40 90 15 230
Caishi Zhang 65 43 24 30 11 149

All Works

Loading papers...

Rankless by CCL
2026